Financial Toxicity and Quality of Life After Bone Marrow Transplant: A Longitudinal, Prospective Study
Authors:
- S. M. Qasim HussainiSHS. M. Qasim Hussaini
- Supriya MaheshwariSMSupriya Maheshwari
- Sanghee HongSHSanghee Hong
- Lauren BohannonLBLauren Bohannon
- Dinesh Pal MudaranthakamDMDinesh Pal Mudaranthakam
- Rachel ForcinoRFRachel Forcino
- Manuel R. Espinoza-GutarraMEManuel R. Espinoza-Gutarra
- Andres AzueroAAAndres Azuero
- Courtney P. WilliamsCWCourtney P. Williams
- Gabrielle B. RocqueGRGabrielle B. Rocque
- 23 September 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Abstract
PURPOSE: Financial toxicity is common after bone marrow transplant (BMT) and is associated with worse quality of life, but longitudinal patterns remain poorly understood. METHODS: We conducted a prospective cohort study of insured adults undergoing allogeneic BMT (2018-2023). Financial toxicity (Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy) and quality of life (Functional Assessment of Cancer Therapy [FACT]–General, FACT-BMT) were assessed at baseline and at days (D) 90, 180, and 365. Longitudinal trends were analyzed using mixed-effects models. Relative risks (RR) for financial toxicity and hazard ratios (HR) for post-BMT mortality were estimated using generalized linear mixed-effects and time-varying Cox models. RESULTS: Among 214 transplanted patients, the median age was 58 years (IQR 46-66 year), 62% were male, and 80% were White; 47% had leukemia, 27% myelodysplastic syndrome, and 9% lymphoma; and 31% died by D365. At baseline, 56% reported none/minimal, 26% mild, and 18% moderate/high financial toxicity. Financial toxicity was associated with more cost-cutting behaviors, including reduced spending on food or clothing, use of savings, and prescription nonadherence. Expected probability of ≥mild financial toxicity reduced over time (39% baseline, 34% D90, 30% D180, 26% D365). Across time points, age >65 years and income >$90,000 in US dollars (USD) had 66% and 67% decreased risk of financial toxicity, respectively, compared with counterparts (n = 148, RR, 0.34, 95% CI [0.19 to 0.59]; RR, 0.33 [0.20 to 0.57]). Quality of life (n = 119 alive and with data by D365) with none/minimal or mild financial toxicity improved after transplant compared with baseline but significantly worsened for those with moderate/high financial toxicity over 1 year. Following adjustment for covariables, financial toxicity was not significantly associated with premature death after transplant (n = 214, HR, 1.10 [0.62-1.96]). CONCLUSION: Financial toxicity improved overtime with BMT, but persistent financial hardship was associated with quality of life. These findings support longitudinal screening and financial interventions across the transplant continuum.Keywords
This publication has 30 references indexed in Scilit:
- Incorporating patient‐reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipientsCancer, 2024
- Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2020
- Age and gender differences in financial distress among hematopoietic cell transplant survivorsSupportive Care in Cancer, 2020
- Prevalence and Correlates of Medical Financial Hardship in the USAJournal of General Internal Medicine, 2019
- Relationship between paid leave, financial burden, and patient-reported outcomes among employed patients who have undergone bone marrow transplantationQuality of Life Research, 2019
- Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Cancer, 2016
- Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2016
- Financial Burden in Recipients of Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2014
- The development of a financial toxicity patient‐reported outcome in cancer: The COST measureCancer, 2014
- Economic survivorship stress is associated with poor health‐related quality of life among distressed survivors of hematopoietic stem cell transplantationPsycho-Oncology, 2012